Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients

Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover

(2013) L. Gifre et al.   BONE

Resorption Controls Bone Anabolism Driven by Parathyroid Hormone (PTH) Receptor Signaling in Osteocytes

(2013) Yumie Rhee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives

(2012) Roland Baron et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

(2012) Ulrike Harre et al.   JOURNAL OF CLINICAL INVESTIGATION

The role of osteocalcin in human glucose metabolism: marker or mediator?

(2012) Sarah L. Booth et al.   Nature Reviews Endocrinology

Pathways for Bone Loss in Inflammatory Disease

(2012) Tobias Braun et al.   Current Osteoporosis Reports

Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts

(2011) Maria Almeida et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Arthritis Increases the Risk for Fractures -- Results from the Women's Health Initiative

(2011) N. C. WRIGHT et al.   JOURNAL OF RHEUMATOLOGY

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate

(2010) Alan L. Burshell et al.   BONE

PINP as an aid for monitoring patients treated with teriparatide

(2010) Mika Tsujimoto et al.   BONE

Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review

(2010) S. J. Gallacher et al.   CALCIFIED TISSUE INTERNATIONAL

Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women

(2010) Matthew T. Drake et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

(2009) Patrick Garnero et al.   ARTHRITIS AND RHEUMATISM

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

(2009) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis

(2008) M Guler-Yuksel et al.   ANNALS OF THE RHEUMATIC DISEASES

Vitamin K Treatment Reduces Undercarboxylated Osteocalcin but Does Not Alter Bone Turnover, Density, or Geometry in Healthy Postmenopausal North American Women

(2008) Neil Binkley et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis

(2007) Steven Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM